Talwin Side Effects
Generic name: pentazocine
Medically reviewed by Drugs.com. Last updated on Apr 16, 2024.
Note: This document contains side effect information about pentazocine. Some dosage forms listed on this page may not apply to the brand name Talwin.
Applies to pentazocine: oral tablets.
Warning
REMS:
FDA approved a REMS for pentazocine to ensure that the benefits outweigh the risk. The REMS may apply to one or more preparations of pentazocine and consists of the following: medication guide and elements to assure safe use. See the FDA REMS page ([Web]).
- FDA drug safety communication (4/13/2023):500 As part of its ongoing efforts to address the nation’s opioid crisis, FDA is requiring several updates to the prescribing information of opioid pain medicines. The changes are being made to provide additional guidance for safe use of these drugs while also recognizing the important benefits when used appropriately. The changes apply to both immediate-release (IR) and extended-release/long-acting preparations (ER/LA).
- Updates to the IR opioids state that these drugs should not be used for an extended period unless the pain remains severe enough to require an opioid pain medicine and alternative treatment options are insufficient, and that many acute pain conditions treated in the outpatient setting require no more than a few days of an opioid pain medicine.
- Updates to the ER/LA opioids recommend that these drugs be reserved for severe and persistent pain requiring an extended period of treatment with a daily opioid pain medicine and for which alternative treatment options are inadequate.
- A new warning is being added about opioid-induced hyperalgesia (OIH) for both IR and ER/LA opioid pain medicines. This includes information describing the symptoms that differentiate OIH from opioid tolerance and withdrawal.
- Information in the boxed warning for all IR and ER/LA opioid pain medicines will be updated and reordered to elevate the importance of warnings concerning life-threatening respiratory depression, and risks associated with using opioid pain medicines in conjunction with benzodiazepines or other medicines that depress the central nervous system (CNS).
- Other changes will also be required in various other sections of the prescribing information to educate clinicians, patients, and caregivers about the risks of these drugs.
Side effects include:
Dizziness, lightheadedness, euphoria, sedation, nausea.
For Healthcare Professionals
Applies to pentazocine: injectable solution.
General
The most commonly occurring adverse reactions have included nausea, dizziness or lightheadedness, vomiting, and euphoria.
Dermatologic
Postmarketing reports: Soft tissue induration, nodules and cutaneous depressions at injection sites; ulceration (sloughing), severe sclerosis of the skin and subcutaneous tissues and, rarely, underlying muscle; diaphoresis, sting on injection, flushed skin including plethora, dermatitis including pruritus[Ref]
Hypersensitivity
Postmarketing reports: Anaphylaxis, facial edema, toxic epidermal necrolysis[Ref]
Nervous system
Postmarketing reports: Dizziness, lightheadedness, sedation, headache, weakness, flushing, syncope, tremor, paresthesia
Opioids:
Postmarketing reports: Serotonin syndrome[Ref]
Serotonin syndrome has been reported during concomitant use of opioids with serotonergic drugs.[Ref]
Psychiatric
Postmarketing reports: Depression, euphoria, confusion, disorientation, disturbed dreams, insomnia, irritability, excitement, hallucinations[Ref]
Respiratory
Postmarketing reports: Respiratory depression, dyspnea, transient apnea (in infants whose mothers received this drug during labor)[Ref]
Cardiovascular
Postmarketing reports: Circulatory depression, shock, hypertension, tachycardia, syncope[Ref]
Gastrointestinal
Postmarketing reports: Nausea, vomiting, constipation, dry mouth, taste alteration, diarrhea and cramps[Ref]
Hematologic
Postmarketing reports: Depression of the white blood cell count (especially granulocytes), moderate transient eosinophilia[Ref]
Depression of the white blood cell count is usually reversible.[Ref]
Other
Postmarketing reports: Tinnitus, chills[Ref]
Ocular
Postmarketing reports: Visual blurring and focusing difficulty, blurred vision, diplopia, miosis, nystagmus[Ref]
Genitourinary
Postmarketing reports: Urinary retention, alteration in rate or strength of labor contractions[Ref]
Endocrine
Opioids:
Postmarketing reports: Adrenal insufficiency, Androgen deficiency
Cases of adrenal insufficiency have been reported with opioid use, generally use greater than 1 month. Cases of androgen deficiency have been reported with chronic opioid use.
More about Talwin (pentazocine)
- Check interactions
- Compare alternatives
- Reviews (8)
- Dosage information
- During pregnancy
- Drug class: Opioids (narcotic analgesics)
- Breastfeeding
Patient resources
Professional resources
Related treatment guides
References
1. (2001) "Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.